UNSPSC 51373337: Droperidol/fentanyl

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373337 Droperidol/fentanyl is a Commodity-level code that in practice covers a broader range of pharmaceutical products and emergency-response medications than its name alone suggests. Recent state and local solicitations under this code show procurement of naloxone kits, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and community health networks. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The work involves establishing supply agreements with pharmaceutical manufacturers and distributors, negotiating pricing models, ensuring FDA compliance and cGMP certification, and arranging quarterly or regular deliveries to county health facilities, state agencies, and member jurisdictions within the cooperative.

Recent activity concentrates in Florida, Texas, and Minnesota. A representative opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county's community health building, due July 26, 2023. Another is the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to improve prescription fulfillment and cost management outside traditional pharmacy benefit manager arrangements. A third is MMCAP's RFP S1070000015802, posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across Minnesota, Oregon, and other participating state and local facilities through authorized wholesalers, with proposals due March 26, 2026 and contract awards effective July 1, 2026. These solicitations reflect demand for competitive pharmaceutical sourcing, direct-to-manufacturer contracting models, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions.